for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Audentes Therapeutics Inc

BOLD.OQ

Latest Trade

27.75USD

Change

0.00(0.00%)

Volume

207,758

Today's Range

27.08

 - 

28.38

52 Week Range

18.00

 - 

41.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Audentes Therapeutics Reports Q3 Loss Per Share Of $1.00

Nov 7 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $1.00.Q3 EARNINGS PER SHARE ESTIMATE $-1.07 -- REFINITIV IBES DATA.BLA SUBMISSION FOR AT132 FOR TREATMENT OF XLMTM ON-TRACK FOR MID-2020; MAA ON-TRACK FOR SECOND HALF OF 2020.AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $351.5 MILLION.

Audentes Therapeutics Presents New Positive Data From Aspiro

Oct 5 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS PRESENTS NEW POSITIVE DATA FROM ASPIRO, THE CLINICAL TRIAL EVALUATING AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY (XLMTM), AT THE 24TH INTERNATIONAL ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY.AT132 CONTINUES TO BE GENERALLY WELL-TOLERATED WITH A MANAGEABLE SAFETY PROFILE ACROSS BOTH DOSE COHORTS.ENROLLMENT OF PIVOTAL EXPANSION COHORT NEARLY COMPLETE.ON TRACK TO SUBMIT A BLA IN UNITED STATES IN MID-2020 AND A MAA IN EUROPE IN SECOND HALF OF 2020 FOR AT132.

Audentes Therapeutics Posts Q2 Loss Per Share Of $1.01

Aug 6 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.01.Q2 EARNINGS PER SHARE ESTIMATE $-1.03 -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $378.6 MILLION.VECTOR SCREENING STUDIES UNDERWAY FOR AT466 FOR MYOTONIC DYSTROPHY TYPE 1 (DM1); PLAN TO SUBMIT IND IN 2020.

Audentes Therapeutics Presents New Positive Data From Aspiro

May 1 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS PRESENTS NEW POSITIVE DATA FROM ASPIRO, THE PHASE 1/2 CLINICAL TRIAL OF AT132 FOR X-LINKED MYOTUBULAR MYOPATHY, AT 22ND ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY.AUDENTES THERAPEUTICS INC - AT132 HAS BEEN GENERALLY WELL-TOLERATED AND HAS SHOWN A MANAGEABLE SAFETY PROFILE ACROSS BOTH DOSE GROUPS.AUDENTES THERAPEUTICS - NO POSSIBLY OR PROBABLY TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED IN COHORT 1 OF AT132 SINCE SCIENTIFIC UPDATE IN MAY 2018.

Audentes Therapeutics Reports Fourth Quarter 2018 And Full Year Financial Results

Feb 27 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2018 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.AUDENTES THERAPEUTICS INC QTRLY LOSS PER SHARE $0.84.AUDENTES - DECEMBER 31, 2018 CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES, AND RESTRICTED CASH OF $418.1 MILLION, EXPECTED TO FUND OPERATIONS INTO 2021.

Audentes Therapeutics Says Proceeding With Previously Announced Plan To Enroll 3 To 5 Additional Patients In Cohort 2 Of Aspiro Phase 1/2 Study

Jan 31 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS ANNOUNCES NEXT STEPS IN THE DEVELOPMENT OF AT132 TO TREAT XLMTM FOLLOWING COLLABORATIVE INITIAL MEETING WITH FDA UNDER RMAT DESIGNATION.AUDENTES THERAPEUTICS INC - PROCEEDING WITH PREVIOUSLY ANNOUNCED PLAN TO ENROLL 3 TO 5 ADDITIONAL PATIENTS IN COHORT 2 OF ASPIRO PHASE 1/2 STUDY.AUDENTES THERAPEUTICS INC - PROCEEDING WITH PREVIOUSLY ANNOUNCED PLAN TO SELECT OPTIMAL DOSE OF AT132 IN Q2 OF 2019.AUDENTES THERAPEUTICS INC - PLANS TO PROVIDE AN UPDATED DATA PACKAGE TO FDA TO FACILITATE FINAL AGREEMENT ON PATH TO BLA SUBMISSION.

Audentes Therapeutics Plans To File Investigational New Drug Application For AT845 For Treatment Of Pompe Disease In Q3 2019

Jan 7 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS REPORTS ON RECENT PROGRESS AND OUTLINES 2019 KEY PRIORITIES.AUDENTES THERAPEUTICS INC - PLANS TO FILE INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR AT845 FOR TREATMENT OF POMPE DISEASE IN Q3 2019.AUDENTES THERAPEUTICS INC - BALANCE SHEET EXPECTED TO FUND OPERATIONS INTO 2021.

Audentes Therapeutics Qtrly Net Loss Per Share, Basic And Diluted Was $0.97

Nov 6 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.AUDENTES THERAPEUTICS INC QTRLY NET LOSS PER SHARE, BASIC AND DILUTED WAS $0.97.AUDENTES THERAPEUTICS - AS OF SEPT 30, 2018, HAD CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH OF $285.5 MILLION.AUDENTES THERAPEUTICS INC - CURRENT CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES ARE EXPECTED TO FUND OPERATIONS INTO 2021.

Audentes Therapeutics Says Pricing Of Public Offering Of Common Stock

Oct 10 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.AUDENTES THERAPEUTICS - PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5.2 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $29.00 PER SHARE.

Audentes Therapeutics Announces Public Offering Of Common Stock

Oct 9 (Reuters) - Audentes Therapeutics Inc <BOLD.O>::AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AUDENTES THERAPEUTICS INC - INTENDS TO OFFER $150 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up